Supplementary information
Cancer
CANCER
The online version contains supplementary material available at 10.1038/s41467-023-41955-7.We would like to acknowledge the patients and their families, the study investigators, and the clinical site staff. As an investigator-initiated trial, the authors acknowledge Henan Cancer Hospital for providing research facilities and equipment. The study drugs, dalpiciclib and pyrotinib, were provided by Jiangsu Hengrui Pharmaceuticals Co., Ltd. This study was funded by the XINRUI Project of Cancer Supportive Care and Treatment Research (cphcf-2021-011, M.Y.).